MedTrace Logo

18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma

NCT04317313 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2021-10-21

Study results available
· View outcomes & findings →

Summary

This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

OTHER

FDG PET radiomic feature evaluation

A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features. In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Mei Tian, M.D. · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-07-30
Completion
2021-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04317313 on ClinicalTrials.gov